Abstract
Importance Chronic nausea and vomiting syndromes (NVS) are prevalent and debilitating disorders. Putative mechanisms include gastric neuromuscular disease and dysregulation of brain-gut interaction, but clinical tests for objectively defining gastric motor function are lacking.
Objective A novel medical device enabling non-invasive body surface gastric mapping (BSGM) was developed and applied to evaluate NVS pathophysiology.
Design A case-control study where BSGM was performed in NVS patients and matched controls using Gastric Alimetry (Alimetry, New Zealand), comprising a conformable high-resolution array (8×8 electrodes; 20 mm inter-electrode spacing), wearable Reader, and validated symptom logging App. Continuous measurement encompassed a fasting baseline (30 min), 482 kCal meal (10 min), and 4-hr post-prandial recording.
Setting Multicenter study in Auckland, New Zealand and Calgary, Canada.
Participants 43 NVS patients (gastroparesis and Rome IV chronic NVS) and 43 matched controls.
Main outcomes and measures Symptom severity and quality of life were measured using Patient Assessment of Upper Gastrointestinal Disorders-Symptom Severity Index (PAGI-SYM), Gastroparesis Cardinal Symptom Index (GCSI), and Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life (PAGI-QOL) instruments. Health psychology metrics included the State Trait Anxiety Inventory Short Form (STAI-SF) and Patient Health Questionnaire-2 (PHQ-2) questionnaires. Spectral analyses including frequency, amplitude, and fed-fasting power ratio. Spatial biomarker analyses included spatial frequency stability and average spatial covariance.
Results Meal responses were impaired in NVS, with reduced amplitudes compared to controls (median 23.3 vs 38.0 µV, p<0.001), impaired fed-fasting power-ratios (1.1 vs 1.6, p=0.02), and disorganized slow-waves (spatial frequency stability 13.6 vs 49.5; p<0.001). However, two distinct NVS subgroups were evident with indistinguishable symptoms (all p>0.05). A majority (62%) had normal BSGM studies (all biomarkers non-significant vs controls) with increased psychological comorbidities (43.5% vs 7.7%; p=0.03) and anxiety scores (median 16.5 vs 13.0; p=0.035). A smaller subgroup (31%) had markedly abnormal BSGM, with test biomarkers correlating with symptoms (nausea, pain, excessive fullness, early satiety, bloating; all r>0.35, p<0.05).
Conclusions and Relevance NVS patients share overlapping symptoms, but comprise distinct underlying phenotypes as revealed by a novel BSGM device. These phenotypes correlate with symptoms, which should inform clinical management and allocations into therapeutic trials.
Question How does body surface gastric mapping, a novel non-invasive medical device for evaluating gastric motility, aid assessment of patients with chronic nausea and vomiting.
Findings Two subgroups were revealed in chronic nausea and vomiting syndromes, which could not be differentiated by symptoms alone. Where body surface gastric mapping was normal, symptoms correlated with psychological comorbidities, and where body surface gastric mapping was abnormal, symptoms correlated with gastric electrophysiology metrics.
Meaning Distinct phenotypes revealed by body surface gastric mapping correlate with symptoms, which should inform targeted clinical management and allocations into therapeutic trials.
Competing Interest Statement
GOG, PD and AG hold grants and intellectual property in the field of gastrointestinal electrophysiology. GOG and AG are founders and Directors of Alimetry Ltd. GOG is Director in The Insides Company. SC, SW, CD, GS, PD, JW and CNA are members of Alimetry Ltd. PD is a Director in FlexiMap Ltd. The remaining authors have no conflicts of interest to declare.
Funding Statement
This work was supported by the Health Research Council of New Zealand, Royal Society Te Apārangi, and the John Mitchell Crouch Fellowship from the Royal Australasian College of Surgeons.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This was a case-control study conducted in Auckland, New Zealand, and Calgary, Canada. Ethical approvals were given by The Auckland Health Research Ethics Committee (AHREC; AH1130) and Conjoint Health Research Ethics Board (CHREB; REB19-1925). All patients provided informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Joint first authors
Data Availability
Data produced in the present study are available upon reasonable request from the corresponding author.
